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Recent clinical studies suggest that adoptive transfer of donor-derived natural killer (NK)
cells may improve clinical outcome in hematological malignancies and some solid tumors
by direct anti-tumor effects as well as by reduction of graft versus host disease (GVHD).
NK cells have also been shown to enhance transplant engraftment during allogeneic
hematopoietic stem cell transplantation (HSCT) for hematological malignancies.The limited
ex vivo expansion potential of NK cells from peripheral blood (PB) or umbilical cord blood
(UCB) has however restricted their therapeutic potential. Here we define methods to effi-
ciently generate NK cells from donor-matched, full-term human placenta perfusate (termed
Human Placenta-Derived Stem Cell, HPDSC) and UCB. Following isolation from cryopre-
served donor-matched HPDSC and UCB units, CD56+CD3− placenta-derived NK cells,
termed pNK cells, were expanded in culture for up to 3 weeks to yield an average of 1.2 bil-
lion cells per donor that were>80% CD56+CD3−, comparable to doses previously utilized
in clinical applications. Ex vivo-expanded pNK cells exhibited a marked increase in anti-
tumor cytolytic activity coinciding with the significantly increased expression of NKG2D,
NKp46, and NKp44 (p<0.001, p<0.001, and p<0.05, respectively). Strong cytolytic activ-
ity was observed against a wide range of tumor cell lines in vitro. pNK cells display a distinct
microRNA (miRNA) expression profile, immunophenotype, and greater anti-tumor capacity
in vitro compared to PB NK cells used in recent clinical trials. With further development,
pNK may represent a novel and effective cellular immunotherapy for patients with high
clinical needs and few other therapeutic options.
Keywords: placental-derived natural killer cells, ex vivo expansion, anti-tumor cytolytic activity, miRNA, cellular
immunotherapy
INTRODUCTION
The critical role of natural killer (NK) cells in the defense against
cancer and virus infection has been increasingly appreciated since
they were first discovered in mice more than 30 years ago (Her-
berman et al., 1975a,b). Clinical studies exploring the biological
activities of NK cells in the treatment of malignant disease and
during allogeneic hematopoietic stem cell transplantation (HSCT)
have provided promising results. Transplant studies have suggested
alloreactive NK cells could mediate potent anti-leukemia effects
without causing graft versus host disease (GVHD). In human
leukocyte antigen (HLA)-mismatched, haploidentical allogeneic
stem cell transplants (SCT), NK alloreactivity was associated with a
higher rate of survival, a lower rate of relapse,and treatment related
mortality post transplantation (Ruggeri et al., 1999, 2002; Velardi
et al., 2002). Several clinical studies have convincingly demon-
strated that adoptive transfer of NK cells isolated from peripheral
blood (PB) of haploidentical donors can be successfully used
for immunotherapy in acute myeloid leukemia (AML) patients
(Miller et al., 2005; Rubnitz et al., 2010; Curti et al., 2011). However,
a number of technical challenges have hampered the widespread
application of NK cells in immunotherapy; these include a lim-
ited ability to generate large numbers of effector cells, difficulty
in maintaining high tumoricidal activity during ex vivo expansion
and in vivo therapy, and a limited understanding of NK-specific
tumor targeting profiles. Therefore, there is a need to overcome
these challenges and enable a NK cell-based anti-tumor strategy
in the clinic.
To date, the most utilized source for NK cells in adoptive
immunotherapy is PB (Sutlu and Alici, 2009), with clinically effec-
tive doses reported in the range of 1× 106–9.3× 106 PB NK
cells/kg (Passweg et al., 2004; Miller et al., 2005; McKenna et al.,
2007; Shi et al., 2008; Meyer-Monard et al., 2009; Rubnitz et al.,
2010; Yoon et al., 2010; Curti et al., 2011). Embryonic stem cells
(Woll et al., 2009) and umbilical cord blood (UCB) (Spanholtz
et al., 2010) have also been used as sources of CD34+ cells that
were differentiated into functional NK cells. Previous studies have
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highlighted the potential to selectively isolate and expand NK cells
from UCB for adoptive cell transfer treatment of tumors (Xing
et al., 2010). Over the last decade the phenotype and function of
decidual NK (dNK) cells in placenta development have been stud-
ied extensively (Koopman et al., 2003; Hiby et al., 2004; Kopcow
et al., 2005, 2010; Apps et al., 2011; Male et al., 2011). However,
little information is available on the role of NK cells from placenta
for cellular immunotherapy.
Recently, human placenta has been demonstrated as a novel
and valuable source of multipotential stem/progenitor cells of
mesenchymal and hematopoietic origin for multiple therapeutic
applications (Parolini et al., 2008; Prather et al., 2008). Celgene
Cellular Therapeutics (CCT, a division of Celgene Corporation)
is developing human placenta-derived stem cells (HPDSC) as an
adjunct to UCB cells for allogeneic use in first-degree or second-
degree blood relatives for augmentation of the stem cell graft in
hematopoietic reconstitution. We have established a standardized
procedure to perfuse donated full-term placentas with normal
saline to recover HPDSC. HPDSC were subsequently processed
to remove red blood cells, non-viable cells and tissue debris fol-
lowed by cryopreservation. HPDSC were neither expanded nor
cultured during processing. The process typically yields 100–500
million total nucleated cells (TNC), approximately 1–5% of which
are CD34+ hematopoietic stem cells (HSCs). We hypothesize that
HPDSC combined with the donor-matched UCB could represent
an effective new source of NK cells that holds potential for further
immunotherapeutic development.
Unlike their antigen-specific lymphoid counterparts, such as
T cells and B cells, NK cells, characterized as CD56+CD3−,
recognize and subsequently kill virus-infected and transformed
cells without prior immunization. NK cells operate via the bal-
ance of signals from inhibitory receptors, such as the killer cell
immunoglobulin-like receptors (KIRs), and the C-type lectin
family receptor: CD94/NKG2, with activating receptors, such as
NKG2D, NKp46, NKp44, NKp30, and CD226 (Smyth et al., 2002;
Huntington et al., 2007). Two major subtypes of CD56+ NK cells
can be distinguished according to the co-expression of the cell sur-
face marker CD16 (Jacobs et al., 2001). It has been demonstrated
that CD56+CD16− NK cells have very few cytolytic granules,
low or no expression of KIRs, high expression of KLR family
members and are capable of producing cytokines and chemokines
upon activation. CD56+CD16+NK cells have abundant cytolytic
granules and high expression of KIRs. PB contains more than
90% CD56+CD16+ NK cells, while more than 90% of NK
cells in lymph nodes do not express CD16 (Cooper et al., 2001;
Fehniger et al., 2003). Results from developmental NK cells stud-
ies suggest that the CD56+CD16+ NK cells are derived from
the CD56+CD16− NK cells (Lanier et al., 1986; Ferlazzo et al.,
2004; Freud et al., 2005). In addition to cell surface markers,
different miRNA expression profiles have been associated with
NK cell development, maturation, and function (Bezman et al.,
2010). To date, no study has investigated the miRNA profile start-
ing from donor-matched HPDSC and UCB (hereafter referred to
as “Combo unit”) followed by differentiation into functional NK
cells.
In this study, we report that placenta is a rich source of placenta-
derived NK (pNK) cells that can be readily isolated from Combo
units, followed by ex vivo expansion. We evaluated the prolifer-
ation, immunophenotype, miRNA expression, and activation of
these expanded cells, as well as their cytolytic activities in vitro.
Our results demonstrate that pNK cells can be generated in clini-
cally relevant quantities and may be developed as a highly cytotoxic
cellular product that can be used to treat a wide range of cancers.
MATERIALS AND METHODS
PROCESSING OF HPDSC AND UCB
Postpartum placentas and umbilical cords were procured under
full-informed consent of donors with donor eligibility documen-
tation, and were qualified using a series of tests, including serology,
bacteriology, and HLA typing. HPDSC isolation and recovery was
achieved by cannulation of the umbilical vessels (two arteries and
one vein) under sterile conditions with polyethylene catheters con-
nected to a flow-controlled fluid circuit allowing perfusion of
the placenta. A total of 750 ml of perfusion solution (0.9% NaCl
injection solution USP Grade) (VWR) was collected from each pla-
centa. UCB was obtained by cannulation of the umbilical vein and
collected into a bag containing citrate-phosphate-dextrose (Fen-
wal). Both UCB and perfusate were then processed by red blood
cell depletion using Hetastarch, followed by volume reduction.
The resulting cell populations were cryopreserved in a solution
containing 5% human albumin and 10% DMSO with a controlled
rate freezer prior to final storage in the gas phase of a liquid
nitrogen tank.
ISOLATION OF pNK CELLS FROM HPDSC AND UCB
The donor-matched cryopreserved HPDSC and UCB were ini-
tially thawed, combined, and washed with RPMI 1640 (without
phenol red) (Gibco) containing 5% v/v fetal bovine serum (FBS;
Hyclone Laboratories). In some NK cell expansion studies, periph-
eral blood mononuclear cells (PBMCs) obtained from buffy coat
(Blood Center, NJ, USA) were prepared as an alternate source of
NK cells. After washing, cell pellets were resuspended at 5× 107
cells/ml in RoboSep buffer (StemCell Technologies). DNase I
(0.1 mg/ml solution) (StemCell Technologies) was added to the
cell suspension to a final concentration of 100µl/ml, mixed gently
by pipetting and incubated for 15 min at room temperature (RT)
prior to isolation of NK cells using the EasySep®NK Cell Enrich-
ment Kit (StemCell Technologies). Human NK Cell Enrichment
Cocktail (containing monoclonal antibodies to human cell surface
antigens CD3, CD4, CD14, CD19, CD20, CD36, CD66b, CD123,
HLA-DR, and glycophorin A) was added to the cell suspension
at a final concentration of 50µl/ml and incubated for 10 min
at RT. After incubation with EasySep®Magnetic Microparticles
(final concentration of 100µl/ml) for 5 min at RT, enrichment
of NK cells was performed according to the protocol provided
by the manufacturer (StemCell Technologies). A CD56+CD3−
population was thus collected and ready for further analysis or
cultivation. The following equation was used for the calculation
of the recovery of pNK cells: (purified NK cell count× purified
CD56+CD3−%)/(TNC count× starting CD56+CD3−%).
EX VIVO EXPANSION OF pNK CELLS
Enriched placental CD56+CD3− NK cells were cultured in Start
Medium based on a modification of previously described proto-
cols (Yssel et al., 1984). All components were from Sigma-Aldrich
Frontiers in Immunology | NK Cell Biology May 2013 | Volume 4 | Article 101 | 2
Kang et al. Human placenta-derived NK cells
unless otherwise specified. Briefly, Start Medium was composed
of Iscove’s Modified Dulbecco’s Media (IMDM) (ATCC) supple-
mented with 10% FBS (Hyclone), 35 mg/ml transferrin, 5µg/ml
insulin, 20µM ethanolamine, 1µg/ml oleic acid, 1µg/ml linoleic
acid, 0.2µg/ml palmitic acid, 2.5µg/ml bovine serum albumin
(BSA),and 0.1µg/ml Phytohemagglutinin (PHA-P). NK cells were
resuspended at approximately 2.5× 105/ml in Start Medium plus
Penicillin-Streptomycin (Invitrogen) and 200 IU/ml IL-2 (R&D
Systems). Mitomycin C-treated PBMC and K562 (ATCC) cells
were added together to Start Medium as feeder cells at a final
concentration of 1× 106/ml each. To initiate NK cell expansion,
the feeder cells and NK cell suspension was transferred into a gas
permeable culture bag (American Fluoroseal) and was cultured
in an incubator at 37˚C in 5% CO2. After culturing for 5–7 days,
expanded cell populations were fed with Maintenance Medium
for up to 21 days. Maintenance Medium was composed of IMDM
supplemented with 10% FBS, 2% Human AB serum (Gemini),
Penicillin-Streptomycin, and 200 IU/ml IL-2. Total cell number
and cell viability were assessed using EasyCount (Immunicon) and
EasyCount ViaSure Kit (Immunicon). Fold expansion was calcu-
lated using the absolute number of CD56+CD3−NK cells on Day
21/absolute number of NK cells on Day 0.
BRDU/7-AAD CELL CYCLE ANALYSIS
Expanded cells at different time points as indicated were labeled
with 5-bromo-2′-deoxyuridine (BrdU) (BD Bioscience) and cul-
tured at 37˚C in 5% CO2 for 24 h. The cells were harvested, fixed,
and stained with anti-BrdU and 7-aminoactinomycin-D (7-AAD)
following the protocol provided by the manufacturer. The cell cycle
data was collected via FACSCalibur (BD Biosciences), and analysis
was accomplished with FlowJo (Tree Star, Inc.).
IMMUNOPHENOTYPIC CHARACTERIZATION
The phenotype of mononuclear cells (MNCs) or enriched NK
cells from Combo unit, or expanded cells from Day 7, 14,
21 cultures, was analyzed by multi-color flow cytometry. Cells
were stained with fluorochrome-conjugated monoclonal antibod-
ies against human blood surface antigens: CD56-PerCP/-PE/-
PE-Cy7, CD3-FITC/-APC-Cy7, CD16-FITC/-PerCP, CD158b-
PE (KIR2DL2/2DL3), CD158e1-PE (KIR3DL1), NKG2D-APC,
NKp46-APC, NKp44-PE, NKp30-PE, CD226-PE, 2B4-PE (all pur-
chased from BD Biosciences Pharmingen), and CD94-PE (R&D
Systems). All analyses were performed using FACSCanto I (BD
Biosciences) and FlowJo analysis software.
PKH26/TO-PRO-3 CYTOTOXICITY ASSAY
Natural killer cell in vitro cytotoxicity was examined using NK cells
as effector cells and various tumor cell lines as target cells. Tar-
get cells were labeled with PKH26 (Sigma-Aldrich) (Lee-MacAry
et al., 2001; Ferlazzo et al., 2004), placed in 96-well U-bottom
tissue culture plates and incubated with effector cells at various
effector to target (E:T) ratios in 200µl RPMI 1640 supplemented
with 10% FBS. After 4 h incubation at 37˚C in 5% CO2, cells
were harvested and TO-PRO-3 (Invitrogen) was added to cul-
tures at 1µM final concentration followed by FACS analysis using
BD FACSCanto I. Cytotoxicity was expressed as the percentage
of dead cells (PKH26+TO-PRO-3+) within the total PKH26+
target tumor cells.
LACTATE DEHYDROGENASE RELEASE ASSAY
Alternatively, NK cell in vitro cytotoxicity was examined by lactate
dehydrogenase (LDH) release assay using CYTOTOX 96®colori-
metric cytotoxicity assay kit (Promega). In this assay, effector
cells and target cells were placed in 96-well U-bottom tissue cul-
ture plates and incubated at various E:T ratios in 100µl RPMI
1640 without phenol red (Invitrogen) supplemented with 2%
human AB serum and incubated for 4 h at 37˚C in 5% CO2.
After incubation, 50µl supernatant was transferred to the enzy-
matic assay plate for detection of LDH activity as instructed by
the manufacturer. Cytotoxicity was calculated using the following
equation: % Cytotoxicity= (experimental release – effector spon-
taneous release – target spontaneous release)/(target maximum
release – target spontaneous release)× 100.
miRNA PREPARATION AND QUANTITATIVE PCR
MicroRNA was isolated from 0.5 to 1.5× 106 cells using a MIR-
VANA™miRNA Isolation Kit (Ambion) following the protocol
provided by manufacturer. The concentration and purity of the
recovered small RNA was determined by measuring its absorbance
at 260 and 280 nm. Purified RNA samples were subjected to
cDNA synthesis using TAQMAN®Reverse Transcription Reagents
(Applied Biosystems) followed by real-time PCR analysis by the
7900HT Fast Real-Time PCR System. Human miRNA Arrays
(Applied Biosystems) were used for gene expression profiling and
miRNA profiling. For each miRNA, the mean∆Ct from real-time
PCR was calculated as∆Ctmean=mean(Ctsample) – mean(Ctendo),
where Ctsample is the Ct value of a miRNA and Ctendo is the Ct
value of the endogenous control. miRNAs were unique to pNK
or PB NK if they met the following criteria: (i) ∆Ctmean < 0, (ii)
|∆Ctmean|≥ 2×Ctendo_SD, where |∆Ctmean| is the absolute value
of ∆Ctmean and Ctendo_SD is the standard deviation of the Ctendo,
and (iii) the miRNAs that satisfied the previous two criteria were
exclusive to the cell type. The rationale for using the aforemen-
tioned criteria was to confirm that a miRNA is abundant in at
least one donor sample, in comparison to the endogenous con-
trol. Donor samples without detectable levels of a miRNA were
numerically ignored when averaging the Ct values. A negative
∆Ctmean along with two standard deviations from the control
gene ensures that the particular gene is relatively abundant. Addi-
tionally, all of the standard deviations of the reference genes were
less than 0.25, which confirms the quality of the control. Sig-
nificantly expressed miRNAs between pNK and PB NK, as well
those between Day 0 pNK and Day 21 pNK were determined
by a two-sample t -test (p value of 0.01 significance level) on the
∆Ct values. Expression fold changes were calculated according to
R= 2(∆Ct1_mean−∆Ct2_mean) where R is the fold change (Livak and
Schmittgen, 2001);∆Ct1_mean is the average∆Ct of pNK on Day
0, and∆Ct2_mean is the average∆Ct of PB NK or expanded pNK.
miRNA TARGET PREDICTION AND PATHWAY ANALYSIS
A search for miRNAs that were unique to either PB NK and pNK,
as well as those that were highly expressed in expanded pNK, was
conducted within seven miRNA target gene prediction databases
(Diana-microT, miRDB, miRTar, microRNA.org, MicroCosmTar-
gets, picTar, and TargetScan) and three experimentally validated
target gene databases (TarBase, miRecords, and miRTarBase) by
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using medium to high stringency search criteria. Genes that were
predicted by five or more databases were considered as high confi-
dence targets. Such targeted genes were then examined in pathway
analysis (Ingenuity Systems) in order to determine the associated
signaling pathways and cellular functions. Pathways were scored
and ranked based on their p-values.
RESULTS
PHENOTYPIC PROFILE OF HPDSC NK CELLS
Human placenta-derived stem cells was harvested from three pla-
centas separately and analyzed for cell surface markers by flow
cytometry and compared to the donor-matched UCB. The compo-
sition of NK cells identified by CD56+CD3− expression was not
substantially different between HPDSC (0.70± 0.24%) and the
donor-matched UCB (0.63± 0.36%) (n= 3). The CD56+CD3−
NK cells were then examined in greater detail using fluorescence-
conjugated monoclonal antibodies against specific NK recep-
tors. The two-sample t -test was used to determine if population
means were equal in HPDSC and UCB. As shown in Figure 1A,
NK cells from three pairs of donor-matched HPDSC and UCB
units exhibited phenotypic similarities, with no significant differ-
ences in expression of sub-populations such as CD56+CD16−,
CD56+CD16+, NKG2D, CD94, KIR3DL1, and KIR2DL2/L3.
After NK expansion for 21 days separately, HPDSC NK, and UCB
NK cells showed comparable cytotoxicity against K562 cells at var-
ious E:T ratios, indicating functional similarity between HPDSC
and UCB NK cells after expansion (Figure 1B).
Based on these similar phenotypic and functional characteris-
tics and in order to increase the starting cell number, HPDSC and
donor-matched UCB units were combined into one Combo unit,
to be used as the starting material for further cell expansion.
ISOLATION AND CHARACTERIZATION OF pNK FROM CRYOPRESERVED
COMBO UNITS
To qualify pNK as a reliable feed stock for this study and for future
clinical production, a series of NK cell isolation experiments were
performed to evaluate the consistency of recovery of pNK cells
from the cryopreserved Combo units. Among 30 isolation pro-
cedures performed, an average number of 1.5× 107 pNK cells
were recovered, enriching the abundance of CD56+ CD3− cells
approximately 25-fold (71% compared to 3% in the starting mate-
rial) (Table 1; Figures 2B,C). Our results indicated nearly 90%
recovery of pNK cells from the cryopreserved Combo units.
To compare pNK cells to PB NK cells, pNK cells from 16
Combo units and NK cells from 13 units of buffy coat obtained
from PB were subjected to an extensive immunophenotypic char-
acterization. The expression of cell surface markers, including
KIRs (KIR3DL1, KIR2DL2/3), CD94, NKG2D, natural cytotoxicity
receptors NCRs (NKp46, NKp44, and NKp30), 2B4, and CD226
was evaluated. Significant differences were observed in 7 out of
11 sub-populations, including CD56+CD16−, CD56+CD16+,
KIR2DL2/3+, NKp46+, NKp30+, 2B4+, and CD94+ (Figure 2A;
Table 2). Notably, most (79%) of the PB NK cells displayed the
mature CD56+CD16+ phenotype, while a majority of the pNK
population (>60%) were immature CD56+CD16− cells.
In attempts to compare gene expression profiles in pNK cells
to PB NK cells, we discovered that individual donor variations
FIGURE 1 | Comparison of NK cells from donor-matched HPDSC and
UCB units. (A) Immunophenotypic characterization of NK cells from
donor-matched HPDSC and UCB units, the two-sample t -test was used to
determine if population means are equal in HPDSC and UCB. (B)
Cytotoxicity of expanded NK cells from donor-matched HPDSC and UCB
units against K562 cells.
Table 1 | NK cell isolation from 30 cryopreserved Combo units.
Starting
TNC count
Purified
NK cell count
Purity
(% CD56+CD3)
Starting Purified
Range (min, max) 4.90E+07,
9.76E+08
3.97E+05,
5.90E+07
0.56,
13.9
23.1,
89.1
Median 3.80E+08 1.02E+07 2.40 79.80
Average 3.95E+08 1.46E+07 2.88 71.18
SD 2.46E+08 1.36E+07 2.63 20.86
SD, standard deviation.
in gene expression profiles were too large to evaluate differences
between the placenta and PB NK sources. As an alternative strat-
egy, differences were further explored by miRNA analysis using
TaqMan Array Human MicroRNA Cards to compare expres-
sion of 365 miRNAs in pNK and PB NK cells. These analy-
ses identified four miRNAs unique to pNK cells (has-miR-337,
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FIGURE 2 | Phenotypic characterization of pNK cells in comparison with
PB NK cells. (A) Flow cytometric identification of NK cells from Combo unit
and PB. CD56+CD3− gated NK cells expressed a repertoire of receptors
important for regulating NK-cell activity, including CD16, KIR3DL1, NKG2D,
KIR2DL2/L3, NKp46, CD94, CD226, NKp44, NKp30, and 2B4. (B) Percentage
of CD56+CD3− pNK cells from Combo unit prior to NK cell isolation. (C)
About 90% CD56+CD3− NK cells from Combo unit was achieved after NK
cell isolation.
Table 2 | Comparison of sub-populations within pNK and PB NK cell
phenotype.
NK sub-populations Combo (n=16 U) PB (n=13 U) pValue
Mean (%) SD Mean% SD
CD16− 60.94 16.58 21.38 14.00 ***
CD16+ 39.05 16.58 78.63 14.01 ***
KIR3DL1+ 12.31 8.11 7.07 8.28 NS
KIR2DL2/L3+ 21.89 8.65 9.46 11.31 **
NKG2D+ 42.11 17.79 29.88 22.64 NS
NKp46+ 6.98 4.33 18.86 13.97 *
CD226+ 15.97 6.66 26.75 23.31 NS
NKp44+ 9.48 5.27 4.89 6.40 NS
NKp30+ 39.08 19.06 18.99 20.86 **
2B4+ 11.07 5.90 4.46 6.45 *
CD94+ 71.31 13.94 26.17 30.49 ***
NS, not significant; *p< 0.05; **p<0.01; ***p<0.001.
has-miR-422a, has-miR-549, and has-miR-618) and eight miRNAs
uniquely expressed by PB NK cells (has-let-7b, has-miR-146b, has-
miR-19b, has-miR-24, has-miR-347, has-miR-381, has-miR-517c,
and has-miR-631). The pNK-unique miRNAs have not been well
characterized except hsa-miR-337, which has been associated with
chondrogenesis as a regulator of TGFBR2 expression (Zhong et al.,
2012). Additionally, 20 miRNAs were expressed at a significantly
higher level, and 29 miRNAs were expressed at a significantly lower
level in pNK cells compared to PB NK cells (Tables 3 and 4). Target
gene prediction analysis returned 14 highly expressed miRNAs in
pNK and 24 highly expressed miRNA in PB NK with more than
one target gene (Table 5). Thus PB NK cells and pNK cells display
distinct miRNA expression patterns.
EX VIVO EXPANSION OF pNK CELLS
Starting from an average of 10 million pNK cells after isolation
procedures, we attempted a series of optimizations of the pNK
cell expansion process based on a previously described protocol
for expansion of cytotoxic and helper T cells (Yssel et al., 1984).
First, to optimize the feeder cell concentration, K562 cells and
allogeneic PBMCs were tested at ratios of, 1:10, 1:5, and 1:1 (K562:
PBMC), with the concentration of PBMC fixed at 1× 106/ml. As
shown in Table 6, the ratio of 1:1 (1× 106/ml K562:1× 106/ml
PBMC) resulted in the greatest NK cell expansion of 98-fold
(n= 14), compared to 32-fold (n= 3) for the 1:5 ratio and 53-fold
(n= 9) for the 1:10 ratio. Therefore the 1:1 ratio was used for fur-
ther pNK cultivation. Next, we tested whether replenishing with
fresh feeder cells could further enhance NK expansion during the
cultivation process. To determine the optimal time window for
replenishing with fresh feeder cells, cell growth kinetics of pNK
cells at Day 7, 14, 21, and 28 were evaluated with BrdU/7-AAD
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Table 3 | Highly expressed miRNAs in pNK cells.
miRNA Fold increase in pNK pValue
hsa-miR-211 5.26 6.73E−03
hsa-miR-520c 5.58 7.70E−03
hsa-miR-125b 7.46 9.26E−04
hsa-miR-100 11.19 4.29E−04
hsa-miR-326 14.50 5.05E−05
hsa-miR-519c 18.74 6.32E−03
hsa-miR-515-5p 20.99 6.88E−03
hsa-miR-450 21.31 3.00E−03
hsa-miR-198 27.97 3.41E−04
hsa-miR-522 33.63 2.56E−03
hsa-miR-518e 39.78 7.17E−03
hsa-miR-497 54.47 8.88E−03
hsa-miR-566 75.98 1.32E−04
hsa-miR-519d 96.65 3.47E−04
hsa-miR-627 98.54 3.42E−04
hsa-miR-524 106.36 7.97E−04
hsa-miR-520g 291.10 3.24E−04
hsa-miR-302c 396.53 3.55E−04
hsa-miR-512-3p 640.56 3.16E−05
hsa-miR-520h 1793.82 9.60E−05
double-staining followed by flow cytometry. As seen in Figure 3,
at Day 7, the majority of cultured NK cells were in S-phase, indi-
cating that the cells were proliferating. The percentage of actively
proliferating/dividing cells decreased substantially during sub-
sequent culture, suggesting Day 7 was the optimal window for
re-stimulation. As shown in the Table 7, addition of fresh K562
and PBMC feeder cells at Day 7 resulted in a threefold increase in
expansion of NK cells. This optimized 21-day NK culture method
was repeated in 20 expansion experiments, yielding an average
of 1.2× 109 CD56+CD3− NK cells with around 80% viability
(Figure 4A).
CHARACTERIZATION OF EX VIVO-EXPANDED pNK CELLS
Immunophenotypic and miRNA changes were characterized in
expanded pNK cells from 12 Combo units in comparison to unex-
panded cells. First, Day 21 pNK cells showed a significant increase
in the expression of activating receptors such as NKG2D, NKp46,
NKp44, and NKp30, and a significant decrease in the expression
of bidirectional receptor 2B4. The expression of inhibitory KIRs,
including KIR3DL1 and KIR2DL2/L3 was similar for expanded
and unexpanded cells (Figure 4B; Table 8).
We have also investigated the immunophenotype of PB NK
expanded using the optimized isolation and expansion proce-
dure established for pNK in nine donors. Comparison studies of
expanded PB NK cells to expanded pNK cells have revealed that
the most profound difference was the lower expression of NKp44
(Table 9). Less cytotoxic activity was also observed with expanded
PB NK cells at Day 21 (42± 7%) (Figure 4C).
Moreover, Expression of 23 miRNAs was increased while
31 other miRNAs were downregulated after ex vivo expansion
(Table 10). Interestingly, one of the miRNAs found to be upregu-
lated was has-miR-155, which when overexpressed has been shown
Table 4 | Highly expressed miRNAs in PB NK cells.
miRNA Fold increase in PB NK pValue
hsa-miR-331 1.43 5.33E−03
hsa-miR-186 1.90 4.54E−03
hsa-miR-17-5p 2.38 2.34E−03
hsa-miR-26a 2.66 2.36E−03
hsa-miR-133b 2.69 8.19E−04
hsa-miR-181b 2.77 4.42E−03
hsa-miR-222 2.83 5.76E−03
hsa-miR-197 3.00 5.48E−05
hsa-miR-146b 3.05 2.92E−03
hsa-miR-342 3.06 3.23E−04
hsa-miR-181d 3.08 3.41E−03
hsa-miR-155 3.12 8.24E−04
hsa-miR-484 3.18 1.23E−03
hsa-let-7g 3.18 2.08E−03
hsa-miR-200c 3.66 1.91E−03
hsa-miR-181c 3.83 2.72E−04
hsa-miR-191 4.06 3.16E−04
hsa-miR-596 4.14 7.06E−03
hsa-miR-142-5p 4.63 4.84E−04
hsa-miR-95 4.86 2.99E−03
hsa-let-7a 5.04 3.91E−04
hsa-miR-21 5.10 2.87E−04
hsa-miR-152 5.46 1.76E−03
hsa-miR-642 5.56 4.70E−04
hsa-miR-24 5.91 2.54E−05
hsa-miR-10a 14.56 5.71E−03
hsa-miR-429 31.74 5.70E−03
hsa-let-7b 108.34 4.66E−05
hsa-miR-199b 2819.55 3.05E−03
to increase NK cell function via enhanced induction of IFN-γ
(Trotta et al., 2012).
The cytolytic activity of expanded pNK was evaluated in a
FACS-based PKH26/TO-PRO-3 cytotoxicity assay against K562
cells. As shown in Figure 4C, while unexpanded pNK cells showed
minimal cytolytic activity, there was a significant enhancement of
cytotoxicity against K562 cells by pNK cells at Day 21 versus Day 14
at an E:T ratio of 10:1 (63± 15% versus 45± 4%, p< 0.001). The
increase in cytolytic activity after 21-day expansion was associated
with the increased expression in activating receptors (Table 8) and
miRNAs (Table 10). Extended cultivation to 28 days did not result
in further increases in activity.
IN VITRO ANTI-TUMOR CYTOLYTIC ACTIVITY OF EXPANDED pNK CELLS
To further evaluate expanded pNK cell activity against a range of
tumor types, 11 additional tumor cells lines were co-cultured with
Day 21 expanded pNK cells, and NK cell cytolytic activity was mea-
sured at E:T ratios of 10:1, 5:1, 2:1, and 1:1 in a 4-h LDH release
assay. At an E:T ratio of 10:1, expanded pNK cells exhibited greater
than 50% cytotoxicity against multiple tumor cell lines, includ-
ing U937 (89.2± 9.8%), WERI-RB-1 (73.3± 11.8%), RPMI8226
(61.3%± 1.3%), HCT-116 (61± 5.1%), U266 (57.4± 4.7%), as
well as and K562 cells (88.6± 5.6%) (Figure 5). Cytolytic activity
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Table 5 | Differentially regulated miRs and their validated target genes in pNK, compared to PB NK.
miR Experimentally validated genes
HIGHLY EXPRESSED MIRNAS IN PB NK
hsa-let-7a TRIM71 (7) HMGA1 (4) LIN28A (3) ACP1 (2) E2F2 (2) SMOX (1)
HMGA2 (6) THBS1 (4) CASP3 (3) RTCD1 (2) ITGB3 (2) MYC (1)
UHRF2 (5) NRAS (3) PRDM1 (2) CCND2 (2) LIN28 (1) TUSC2 (1)
MED28 (4) EIF2C4 (3) DICER1 (2) SLC20A1 (2) NF2 (1) BCL2 (1)
ZFP36L1 (1) NKIRAS2 (1) EGR3 (1) IL6 (1) NEFM (1)
hsa-let-7b* HMGA2 (6) CDC25A (3) GRPEL2 (2) NXT2 (2) CDIPT (1) SLC25A13 (1)
IGF2BP1 (5) AURKB (3) MARS2 (2) EIF2C3 (2) CDKAL1 (1) SLC25A1 (1)
TMEM2 (5) DHX57 (3) MRM1 (2) CCNA2 (2) CSNK1D (1) UHRF1 (1)
LIN28B (5) FNDC3A (3) POM121 (2) CCNF (2) DOCK5 (1) C20ORF72 (1)
CCNJ (5) RDH10 (3) PXDN (2) EDEM3 (2) FADS2 (1) SCAMP3 (1)
CDC34 (5) SLC25A24 (3) SCYL1 (2) TRABD (2) FAM96A (1) C2ORF18 (1)
IGF2BP2 (5) SNAP23 (3) SLC25A32 (2) PLAGL2 (2) GPR56 (1) CIAO1 (1)
DMD (5) LIN28A (3) SPRYD4 (2) FARP1 (2) IPO4 (1) BIRC6 (1)
E2F6 (5) PRDM1 (3) TAF9B (2) C7ORF58 (2) KIAA0409 (1) AURKA (1)
HMGA1 (4) NRAS (3) TTC9C (2) LIN28 (1) NEDD4 (1) ALG3 (1)
PGRMC1 (4) RRM2 (3) DLC1 (2) BCL7A (1) OPRS1 (1) ARID3A (1)
THBS1 (4) CCND1 (2) CCND2 (2) ACTG1 (1) RHOB (1) CCBL2 (1)
PDE12 (4) ATP6V1F (2) DICER1 (2) AARSD1 (1) RHOG (1) RRP1B (1)
E2F5 (4) GEMIN7 (2) GTF2I (2) ANAPC1 (1) SLC1A4 (1) TAB2 (1)
hsa-let-7g HMGA2 (6) EIF4G2 (5) IGF2BP1 (5) COL1A2 (3) BCL2L1 (1)
hsa-miR-10a NCOR2 (5) MAP3K7 (4) HOXA1 (1) USF2 (1) BTRC (1)
hsa-miR-133b BCL2L2 (3) MCL1 (2)
hsa-miR-146b* TRAF6 (7) IRAK1 (5) MMP16 (2) CARD10 (1)
hsa-miR-152 DNMT1 (5) HLA-G (2)
hsa-miR-155 SOCS1 (5) DET1 (4) SPI1 (3) SMAD1 (2) TM6SF1 (1) RAB34 (1)
TSHZ3 (5) IKBKE (3) MEIS1 (2) TRAM1 (2) FOXO3 (1) RAB6A (1)
HIVEP2 (5) PHF17 (3) SMAD2 (2) TRIP13 (2) ARL5B (1) SYPL1 (1)
TAB2 (4) BACH1 (3) CYR61 (2) FGF7 (2) ATG3 (1) VAMP3 (1)
JARID2 (4) RCN2 (3) TP53INP1 (2) KRAS (2) ATP6V1C1 (1) WDFY1 (1)
CEBPB (4) RCOR1 (3) ANKFY1 (2) HIF1A (2) BET1 (1) ETS1 (1)
ARID2 (4) ZNF652 (3) CHAF1A (2) C5ORF41 (2) CBFB (1) INPP5D (1)
DHX40 (4) MYB (3) CLDN1 (2) IKBIP (2) DNAJB1 (1) PAPOLA (1)
PICALM (4) TLE4 (3) MYO10 (2) TWF1 (2) DSG2 (1) SERTAD2 (1)
TRIM32 (4) CSF1R (3) NARS (2) CUX1 (2) FMNL2 (1) ERMP1 (1)
ZIC3 (4) FAR1 (3) PHC2 (2) SLA (2) PKN2 (1) C3ORF58 (1)
KBTBD2 (4) ZNF236 (3) SDCBP (2) AGTR1 (1) PRAF2 (1) HNRNPA3P1 (1)
MSH2 (1) PELI1 (1)
hsa-miR-17-5p E2F1 (1)
hsa-miR-181b GRIA2 (4) GATA6 (4) TIMP3 (4) MAP3K10 (3) NLK (2) PLAG1 (2)
CYLD (2) VSNL1 (1) KAT2B (1) BCL2 (1)
hsa-miR-181c GATA6 (4) KRAS (3) NLK (2) NOTCH4 (2) NOTCH2 (1)
hsa-miR-181d GATA6 (3) NLK (2) BCL2 (1)
hsa-miR-186 AKAP12 (1)
hsa-miR-191 TMC7 (2) SOX4 (1)
(Continued)
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Table 5 | Continued
miR Experimentally validated genes
hsa-miR-197 FBXW7 (4) DPH1 (2) UMPS (2) CLIC1 (1) HNF4A (1) FOXO3 (1)
CHIC2 (4) ALMS1 (2) CPNE6 (2) WDR6 (1) PEX13 (1) IL1R1 (1)
ACVR1 (4) CES1 (2) RBM4 (2) NEK4 (1) C1ORF38 (1) CPSF1 (1)
RAB28 (3) ZNF302 (2) CYLD (2) PIPOX (1) MED16 (1) SNX1 (1)
HNRNPD (2) RAD51 (2) RFX1 (2) IGF2AS (1) LRP4 (1) KLF10 (1)
GOLGB1 (2) RXRB (2) IER3 (1) DCBLD2 (1) TSPYL1 (1) AGR2 (1)
TUSC2 (1) EHD2 (1)
hsa-miR-199b LAMC2 (1) HES1 (1)
hsa-miR-200c ZFPM2 (6) ZEB1 (5) ERRFI1 (5) ZEB2 (5) FN1 (5) UBE2I (3)
BAP1 (2) PTPN13 (1) BMI1 (1) JAG1 (1) TUBB3 (1)
hsa-miR-21 TGFBI (5) GLCCI1 (3) RASGRP1 (3) SGK3 (2) ANKRD46 (2) SLC16A10 (1)
NFIB (4) SOX5 (3) MSH2 (3) RP2 (2) ACTA2 (1) TIMP3 (1)
RECK (4) JAG1 (3) PCBP1 (3) SERPINB5 (2) BTG2 (1) TGFBR2 (1)
PDCD4 (3) BMPR2 (3) TOPORS (3) SPRY2 (2) SESN1 (1) NCAPG (1)
FAM3C (3) TIAM1 (3) APAF1 (2) RHOB (2) SOCS5 (1) IL1B (1)
RTN4 (1) PTX3 (1) CDK2AP1 (1)
hsa-miR-222 CDKN1B (5) FOS (5) KIT (4) CDKN1C (3) PPP2R2A (2) MMP1 (1)
SOD2 (1) BBC3 (1) PTEN (1) ICAM1 (1) ESR1 (1)
hsa-miR-24* CDKN1B (4) TRIB3 (4) MAPK14 (2) FURIN (2) BRCA1 (1) NOTCH1 (1)
ACVR1B (4) DND1 (3) NFAT5 (2) MLEC (2) KIAA0152 (1) CDKN2A (1)
KHSRP (1) HNF4A (1) TGFB1 (1)
hsa-miR-26a SMAD1 (5) HMGA1 (5) CDK8 (4) HMGA2 (3) CCND2 (2) CCNE2 (2)
STRADB (5) GSK3B (5) MTDH (4) CPEB4 (3) CTGF (2) LIF (2)
PTEN (5) EZH2 (4) MAP3K2 (4) SERBP1 (2) CDC6 (2) CPEB2 (1)
CPEB3 (1) SMAD4 (1)
hsa-miR-331 ERBB2 (2) CDCA5 (2) KIF23 (1)
hsa-miR-342 BMP7 (1) GEMIN4 (1)
hsa-miR-429 ZFPM2 (6) ZEB1 (6) ERRFI1 (4) ZEB2 (4) WASF3 (3) BAP1 (1)
HIGHLY EXPRESSED MIRNAS IN PNK
hsa-miR-100 MTOR (3) PLK1 (1) FGFR3 (1) IGF1R (1) ATM (1)
hsa-miR-125b LACTB (6) BMF (3) SAMD10 (3) MKNK2 (2) BBC3 (2) DICER1 (1)
BAK1 (5) BMPR1B (3) EIF4EBP1 (3) CBFB (2) QSOX2 (2) JUB (1)
ARID3B (5) ENTPD4 (3) KLF13 (3) LIN28A (2) LIN28 (1) DDX19B (1)
IRF4 (5) TOR2A (3) ULK3 (3) IGF2 (2) C10ORF104 (1) PABPC1 (1)
PRDM1 (4) KCNS3 (3) SLC7A6 (3) NKIRAS2 (2) B3GALT4 (1) AKT1 (1)
SLC35A4 (4) LIN28B (3) SLC7A1 (3) SEL1L (2) UBE2I (1) TP53 (1)
CGN (4) GRIN2A (3) ERBB3 (2) ATXN1 (2) RBM8A (1) CASC3 (1)
PPAT (4) STAT3 (3) CDKN2A (2) RAF1 (2) IGFBP3 (1) E2F3 (1)
CBX7 (3) LIF (3) ABTB1 (2) CYP24A1 (2) MAN1A1 (1) RNF144A (1)
SGPL1 (3) SMARCD2 (3) ARID3A (2) ABCC4 (2) SMO (1) LYPLA2 (1)
PLEKHA8 (1) TP53INP1 (1) VDR (1)
hsa-miR-211 KCNMA1 (3)
hsa-miR-302c ESR1 (2)
hsa-miR-326 PKM2 (2) SMO (1) GLI1 (1) NOTCH2 (1)
hsa-miR-422a** CYP8B1 (2)
(Continued)
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Table 5 | Continued
miR Experimentally validated genes
hsa-miR-519c HIF1A (4)
hsa-miR-519d CDKN1A (4) PPARA (3)
hsa-miR-520c APP (3) CD44 (3)
hsa-miR-520g VEGFA (2)
hsa-miR-520h SMAD6 (3) ABCG2 (2) CDKN1A (2) VEGFA (2) ID1 (1) ID3 (1)
hsa-miR-522 SOX2 (1)
hsa-miR-342 BMP7 (1) GEMIN4 (1)
hsa-miR-429 ZFPM2 (6) ZEB1 (6) ERRFI1 (4) ZEB2 (4) WASF3 (3) BAP1 (1)
*, **Denote that the expression level is significantly higher (2 SD higher) in at least one of the donors than the endogenous control in only the PB or pNK, respectively.
Number in parenthesis denotes the number of databases which indicate that the gene is targeted by the miR, in addition to having been validated previously.
FIGURE 3 | Cell cycle analysis of expanded pNK cells. (A) Representative APC-BrdU/7-AAD cell cycle analysis of ex vivo-expanded pNK at different time
points as indicated. (B) Cell cycle analysis at different phases from ex vivo-expanded pNK at different time points as indicated (n=5).
of expanded pNK cells against tumor lines was dose-dependent.
Taken together, these results demonstrated that expanded pNKs
have the ability to kill a wide variety of tumor cells derived from
leukemia and solid tumors.
DISCUSSION
We have herein described, for the first time, that HPDSC (a
product being developed by CCT for hematopoietic reconstitu-
tion in hematologic diseases requiring transplant) combined with
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donor-matched UCB, are a novel and rich source of pNK cells.
Using a highly robust isolation method, we have achieved large
numbers pNK cells in our experiments (approximately 1.5× 107
cells) from single Combo unit with a high proportion of viable
cells (>70%), of which approximately 71% of the population
is composed of CD56+CD3− cells. To overcome the hurdle of
limited cell number for NK immunotherapy, we established a
21-day feeder cell-based NK cultivation process. Recently, several
groups have successfully shown robust NK cell proliferation using
K562 cells expressing 4-1BB Ligand and membrane-bound IL-15
(mbIL-15) or 4-1BB Ligand and mbIL-21 for expansion (Lee et al.,
Table 6 | Optimization of ratio of feeder cells: K562 to PBMC.
Feeder Ratio
(K562:PBMC)
Donors (n) Fold expansion*
range (min, max)
Average fold
expansion
1:10 9 6, 131 53
1:5 3 11, 54 32
1:1 14 15, 358 98
*Fold expansion= absolute number of CD56+CD3−NK cells on Day 21/absolute
number of NK cells on Day 0.
Table 7 | Effect of feeder replenishing at different time points.
Day of
stimulation
Donors (n) Fold expansion
range (min, max)
Average fold
expansion
Day 0 10 17, 83 41
Day 0+Day 7 10 48, 395 148
2010; Denman et al., 2012; Lapteva et al., 2012). Our initial cul-
ture optimization utilizing unmodified K562 cells and allogeneic
PBMC resulted in an average of 1.2× 109 cells per donor that were
>80% CD56+CD3− and with good consistency across donors. It
is conceivable that potential NK cells with higher fold expansion,
longer telomere, and less senescence (Denman et al., 2012) can be
achieved by switching to genetically modified K562 cells. In addi-
tion, Xing et al. (2010) reported that UCB derived NK cells have
low cytolytic activity due to impaired lytic immunological synapse
formation that can be enhanced by addition of IL-2 during ex vivo
expansion. In our study, while uncultured pNK cells showed lit-
tle cytolytic activity against K562 cells, this activity significantly
increased after 21 days of ex vivo expansion, and was associated
with increased expression of NKG2D, NKp46, NKp44, and several
miRNAs.
In recent years, human placenta has emerged as a valuable
source of several stem/progenitor cell populations of mesenchymal
and hematopoietic origin with therapeutic potential. However, lit-
tle information is available on the role of pNK cells for cellular
immunotherapy. We report here that pNK cells are largely sim-
ilar to UCB NK cells, both phenotypically and functionally. We
can significantly increase the number of feed stock for generat-
ing an NK cell-based therapeutic agent by combining NK cells
from donor-matched HPDSC and UCB. In attempts to compare
gene expression profiles in pNK cells to PB NK cells, we discov-
ered that individual donor variations in gene expression profiles
were too large to evaluate differences between the placenta and
PB NK sources. As an alternative strategy, we performed analy-
sis of miRNA expression, which appeared to be more consistent
across individual donors, to identify profiles that were unique to
FIGURE 4 | Expansion, phenotype and functional characterization
of ex vivo-expanded pNK cells. (A) Cell yield and cell viability of Day
21 expanded pNK cells. (B) Phenotype characterization of Day 21
expanded pNK cells. (C) Cytotoxicity of expanded pNK cells against
K562 at different time points as indicated in comparison with Day 21
expanded PB NK cells.
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Table 8 | Sub-population comparison of Day 21 expanded pNK versus
unexpanded pNK cells.
NK Sub-
populations
Day 21 pNK (n=12 U) Day 0 pNK (n=16 U) pValue
Mean (%) SD Mean (%) SD
CD56+CD16− 35.98 18.18 60.94 16.58 **
CD56+CD16+ 63.80 18.32 39.05 16.58 **
KIR3DL1+ 17.92 13.44 12.31 8.11 NS
KIR2DL2/L3+ 21.10 10.48 21.89 8.65 NS
NKG2D+ 89.28 12.88 42.11 17.79 ***
NKp46+ 88.74 5.34 6.98 4.33 ***
CD226+ 18.79 12.14 15.97 6.66 NS
NKp44+ 64.13 16.65 9.48 5.27 **
NKp30+ 84.53 12.40 39.08 19.06 ***
2B4+ 0.89 0.99 11.07 5.90 ***
CD94+ 74.82 12.45 71.31 13.94 NS
*p< 0.05; **p<0.01; ***p<0.001.
Table 9 | Sub-populations comparison in Day 21 expanded pNK versus
Day 21 expanded PB NK.
NK sub-populations Combo (12 U) PB (9 U) pValue
Mean (%) SD Mean (%) SD
CD16− 35.98 18.18 28.39 7.78 NS
CD16+ 63.80 18.32 71.50 7.78 NS
KIR3DL1+ 17.92 13.44 8.83 6.44 NS
KIR2DL2/L3+ 21.10 10.48 37.40 17.82 *
NKG2D+ 89.28 12.88 73.27 20.06 NS
NKp46+ 88.74 5.34 64.97 17.26 **
CD226+ 18.79 12.14 4.80 1.72 NS
NKp44+ 64.13 16.65 16.00 3.82 **
NKp30+ 84.53 12.40 55.77 1.96 *
2B4+ 0.89 0.99 2.16 1.76 NS
CD94+ 74.82 12.45 71.76 20.35 NS
*p< 0.05; **p<0.01; ***p<0.001.
pNK or PB NK cells. We identified four unique and 20 highly
expressed miRNAs in pNK cells, and eight unique and 29 highly
expressed miRNAs in PB NK cells. Target gene prediction analy-
sis returned 14 highly expressed miRNAs in pNK and 24 highly
expressed miRNA in PB NK with more than one target gene. In
PB NK, highly expressed miRNAs included has-let-7a, has-let-
7g, has-mir-133b, has-mir-181b, and has-mir-181d that target the
anti-apoptotic genes Bcl-2 and Bcl-2L, which may indicate that
PB NK cells are closer to reaching the limit of cell expansion than
pNK cells. Additionally, miRNA hsa-mir-146b is highly expressed
in PB NK cells, and its target TRAF6 has been reported to down-
regulate NF-kB activity, suppress cell proliferation and enhance
chemosensitivity (Paik et al., 2011). TRAF6 plays a critical role in
innate and adaptive immunity (Chiffoleau et al., 2003) in conjunc-
tion with genes such as MAPK14, IL6, and FOS, which are targeted
by has-mir-24, has-mir-7a, and has-mir-222 respectively, all found
Table 10 | Differentially regulated miRNAs during pNK ex vivo
expansion.
miRNA Fold change in Day 21 versus Day 0 pValue
hsa-miR-520g −2820.57 6.33E−05
hsa-miR-520h −2803.02 4.35E−04
hsa-miR-518a −2300.60 5.72E−05
hsa-miR-517b −1669.82 8.11E−05
hsa-miR-451 −1626.65 2.40E−03
hsa-miR-518c −609.88 2.93E−04
hsa-miR-127 −557.55 3.40E−04
hsa-miR-517a −288.89 8.27E−05
hsa-miR-382 −273.34 1.77E−04
hsa-miR-519d −245.09 7.13E−04
hsa-miR-486 −149.95 6.29E−03
hsa-miR-518b −112.10 9.70E−05
hsa-miR-522 −85.30 2.58E−03
hsa-miR-376a −72.14 2.95E−03
hsa-miR-198 −70.93 1.13E−03
hsa-miR-126 −51.46 1.97E−04
hsa-miR-487b −47.68 3.32E−03
hsa-miR-519c −47.52 4.88E−03
hsa-miR-518e −34.89 5.06E−03
hsa-miR-433 −18.07 5.68E−04
hsa-miR-125b −16.66 4.66E−04
hsa-miR-214 −16.38 5.74E−03
hsa-miR-130a −12.98 4.13E−03
hsa-miR-518d −10.75 8.73E−03
hsa-miR-99a −7.91 2.03E−03
hsa-miR-515-3p −4.93 2.50E−03
hsa-miR-95 −4.73 9.30E−04
hsa-miR-30a-3p −3.06 1.20E−03
hsa-miR-30d −2.59 4.32E−03
hsa-miR-26a −1.75 7.81E−03
hsa-miR-191 −1.32 2.12E−03
hsa-miR-331 1.53 6.74E−03
hsa-miR-181c 1.71 1.24E−03
hsa-miR-142-3p 2.24 5.55E−03
hsa-miR-155 2.48 3.47E−03
hsa-miR-24 2.66 1.03E−03
hsa-miR-23a 3.07 8.50E−03
hsa-miR-142-5p 3.21 3.34E−04
hsa-let-7d 3.22 3.29E−03
hsa-miR-195 3.77 2.92E−04
hsa-miR-141 3.80 5.20E−03
hsa-miR-98 3.83 2.96E−03
hsa-miR-222 3.86 7.71E−03
hsa-miR-545 5.28 5.60E−03
hsa-miR-642 7.17 2.82E−04
hsa-miR-21 13.46 1.94E−04
hsa-miR-210 13.87 6.66E−03
hsa-miR-221 21.73 3.04E−03
hsa-miR-34c 45.37 5.26E−04
hsa-miR-135b 49.26 1.17E−03
hsa-miR-34a 66.38 8.08E−03
hsa-miR-10a 72.27 1.27E−03
hsa-miR-380-3p 921.50 1.18E−03
hsa-miR-520a 10892.33 2.38E−05
www.frontiersin.org May 2013 | Volume 4 | Article 101 | 11
Kang et al. Human placenta-derived NK cells
%
 S
p
e
c
if
ic
 L
y
s
is
C
C
R
F-
C
E
M
K
G
-1
K
G
-1
a
K
56
2
K
U
81
2
U
93
7
W
ER
I-R
B
-1
R
PM
I8
22
6
U
26
6
H
C
T-
11
6
H
C
C
22
18
H
T-
29
0
20
40
60
80
100 10:1
5:1
2:1
1:1
FIGURE 5 | Cytotoxicity of ex vivo-expanded Day 21 pNK cells against
a wide range of tumor cell lines. Cytotoxicity of ex vivo-expanded pNK
cells (n=6) against a wide range of tumor cell lines at E:T ratio of 10:1, 5:1,
2:1, and 1:1 as indicated.
in our study to be highly expressed in PB NK. Furthermore, we
identified a has-mir-181 group (has-mir-181b, has-mir-181c, has-
mir-181d) that was threefold higher in PB NK. These miRNAs
target nemo-like kinase, a regulator of Notch signaling, which
plays an important role in the development of NK cells from
CD34+HSCs and IFN-γ production in primary CD56+NK cells
(Cichocki et al., 2011). Lastly, within the group of highly expressed
miRNAs in pNK, we have identified miRNA: mRNA target pairs
comprised of pluripotency markers in stem cells and cell cycle
regulators, such as SOX2, BMPR1, SMO, AKT1, ATM, RAF1, and
MTOR, most of which are not present in the targeted gene list
(both experimental and validated) of miRNAs in PB NK. Fur-
thermore, comparison studies have revealed the higher expression
of NKp44 and greater cytotoxic activity against K562 at Day 21
(42± 7%) from expanded pNK compared to that of expanded PB
NK cells.
In conclusion, we have characterized pNK cells from donor-
matched HPDSC and UCB. pNK cells showed a distinct phenotype
and miRNA profile from PB NK cells. We have demonstrated
that pNK cells can be readily obtained from Combo units. These
cells can be expanded, characterized, and activated to yield clini-
cally relevant quantities of a highly cytotoxic cellular product with
potential as a treatment for a wide range of hematological cancers.
Taken together, the results presented here provide an impor-
tant advance in the development of NK cell-based therapeutic
products.
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